This article has Open Peer Review reports available.
Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety
© Lozenski et al.; licensee BioMed Central Ltd. 2012
Received: 29 March 2012
Accepted: 13 September 2012
Published: 1 October 2012
The disappointing clinical failures of five topical vaginal microbicides have provided new insights into factors that impact microbicide safety and efficacy. Specifically, the greater risk for human immunodeficiency virus type 1 (HIV-1) acquisition associated with multiple uses of a nonoxynol-9 (N-9)-containing product has highlighted the importance of application frequency as a variable during pre-clinical microbicide development, particularly in animal model studies.
To evaluate an association between application frequency and N-9 toxicity, experiments were performed using a mouse model of cervicovaginal microbicide safety. In this model system, changes in cervical and vaginal epithelial integrity, cytokine release, and immune cell infiltration were assessed after single and multiple exposures to N-9.
After the initial application of N-9 (aqueous, 1%), considerable damage to the cervical epithelium (but not the vaginal epithelium) was observed as early as 10 min post-exposure and up to 8 h post-exposure. Subsequent daily exposures (up to 4 days) were characterized by diminished cervical toxicity relative to single exposures of like duration. Levels of pro-inflammatory cytokines released into the cervicovaginal lumen and the degree of CD14-positive immune cell infiltration proximal to the cervical epithelium were also dependent on the number of N-9 exposures.
Rather than causing cumulative cervical epithelial damage, repeated applications of N-9 were characterized by decreased sensitivity to N-9-associated toxicity and lower levels of immune cell recruitment. These results provide new insights into the failure of N-9-based microbicides and illustrate the importance of considering multiple exposure protocols in pre-clinical microbicide development strategies.
The global human immunodeficiency virus type 1 (HIV-1) epidemic currently includes approximately 33 million HIV-1-infected people worldwide, with a particularly high incidence of infection (~23 million individuals) in Sub-Saharan Africa. Since the discovery of HIV-1 over 30 years ago, the face of this global epidemic has changed dramatically, with heterosexual intercourse now considered the predominant route for the spread of the virus. As a result, women are at much greater risk for acquiring HIV-1 and have a much greater need for methods that effectively reduce or eliminate the risk of infection during sexual intercourse. Although condoms (male and female) are highly effective barrier methods, they are not female-controlled and are unlikely to be used with great adherence in developing countries. To answer the critical need for effective female-controlled methods of protection, continued efforts are being directed toward the development of microbicides. A microbicide is a chemical entity that can be applied vaginally or rectally to eliminate or reduce the risk of HIV-1 transmission. Efforts to develop topical vaginal microbicides have resulted in the advancement of many candidate microbicide compounds through pre-clinical studies and clinical trials of both safety and efficacy[2–4].
Unfortunately, clinical trials involving the microbicides COL-1492 (nonoxynol-9 or N-9), Savvy (C31G), Ushercell (cellulose sulfate), Carraguard (carrageenan), and PRO 2000[5–7] failed to demonstrate any product efficacy despite promising activities in pre-clinical studies and apparently acceptable levels of safety in early clinical studies. The results of these failed trials emphasized the urgent need for more stringent pre-clinical protocols, with emphasis on microbicide safety and the use of non-human primate models to evaluate the efficacy and safety of potential microbicides.
The clear need for more thorough pre-clinical evaluations is particularly apparent in retrospective analyses of the development of N-9 as a microbicide. Pre-clinical assessments of N-9 failed to predict the inability of N-9 to inhibit HIV-1 transmission and the adverse effects of N-9 exposure on the risk of infection. Early in vitro studies of N-9, which has been widely used as a spermicidal agent for more than 40 years, yielded promising results, demonstrating that N-9 possessed broad-spectrum activity against several sexually transmitted disease (STD) pathogens, including Chlamydia trachomatis, Neisseria gonorrhoeae, herpes simplex virus type 2 (HSV-2), and HIV-1[10–18]. The widespread and apparently safe use of N-9 as a human contraceptive agent further supported the development of this compound as a topical microbicide. As a consequence, N-9 was advanced into human clinical trials. However, the final phase 2/3 clinical trial of N-9 (formulated as COL-1492 with 52.5 mg N-9 per treatment dose) demonstrated that high frequency use of this product was associated with an almost 2-fold greater risk of HIV-1 acquisition. Increased HIV-1 infection after N-9 application, in hindsight, has been attributed to the disruption of the cervicovaginal epithelial barrier as well as inflammation and irritation associated with N-9 application[9, 19–22]. While these findings ended the further development of N-9 as a microbicide, they also raised new questions about mechanisms by which potential topical microbicides can fail.
The apparent association between N-9 application frequency and increased risk of HIV-1 infection prompted an expansion of our previous N-9 toxicity studies involving a Swiss Webster mouse model of cervicovaginal toxicity. The value of this model system was demonstrated in investigations that reiterated the clinical toxicity of N-9 (after a single application) and paralleled indications of irritation associated with topical application of 1.7% C31G[19, 23, 24]. Furthermore, mouse model experiments involving topical vaginal application of N-9 clearly demonstrated that (i) N-9-associated tissue damage was greatest approximately two to four hours post-application, (ii) epithelial damage was limited to the cervix, and (iii) repair and regeneration of cervical epithelial tissues was essentially complete 24 h after a single application of N-9.
The present studies were conducted using the mouse model of microbicide toxicity to examine the effects of multiple daily exposures to N-9. These experiments were designed to provide a comprehensive assessment of changes in cervicovaginal integrity with respect to post-application exposure duration and the number of topical applications of N-9. The results of these investigations indicated that (i) multiple exposures to N-9 resulted in diminished cervical sensitivity to N-9 application relative to the initial exposure and (ii) cytokine release and CD14-positive cell infiltration subsequent to N-9 exposure varied with the number of exposures. These studies provide new insights into the mechanisms underlying the failure of N-9 as a microbicide and suggest a new parameter for assessing future microbicide candidate molecules.
Five- to six-week-old female outbred Swiss-Webster mice (CFW®) were utilized for all experiments (Charles River Laboratories International, Inc., Wilmington, MA). Mice were synchronized 7 and 3 days prior to the start of each experiment with a 0.2 mL subcutaneous injection of Depo-Provera® (Pharmacia and Upjohn Company) diluted in Lactated Ringer’s Solution (Baxter) for a final dose of 3 mg/animal. Prior to intravaginal application, mice were anesthetized with a formulation of ketamine/xylazine (100–200 mg/kg and 5–10 ng/kg, respectively). Anesthetized animals then received a single intravaginal inoculation (60 μL) of saline or N-9 diluted in saline. Mice treated with saline alone were included as controls at all time points to evaluate the normal tissue morphology in the cervicovaginal mucosa. After treatment, mice were humanely sacrificed and the cervicovaginal tracts were surgically excised and prepared for histological examination. Each experiment evaluated three animals at each time point within each test group. All animal studies conformed to the “Guiding Principle in the Care and Use of Animals” approved by the American Physiological Society, and were approved by The Drexel University College of Medicine Institutional Animal Care and Use Committee (IACUC).
Multiple exposure experiments
Prior to excision of the reproductive tracts, animals were vaginally lavaged using 150 μl Lactated Ringer’s Solution (Baxter) by reverse pipetting. Lavage fluids were collected and stored at −80°C prior to analyses of cytokine content. The cervicovaginal tract was then excised, formalin-fixed, and embedded in paraffin using standard procedures. Tissue sections set aside for further processing were chosen to show epithelial tissues from the lower vaginal tract and the cervix. Sections were stained with hematoxylin and eosin (H&E) for assessment of tissue damage; representative fields from each treatment group were imaged and documented using deconvolution microscopy.
Measurement of cytokine levels in vaginal lavage fluids
Cytokine levels in collected vaginal lavages were measured using a Luminex 100/200 instrument (Luminex Corporation, Austin, TX). Two murine pro-inflammatory cytokines – interleukin-1β (IL-1β) and interleukin-6 (IL-6) – were measured using commercially available plates (Millipore). Lavage samples were thawed on ice and then centrifuged for 5 minutes at a high speed to pellet any debris or mucus and to prevent plate filter clogging. Samples (25 μL per well) were added to the plate in duplicate and processed as described by the manufacturer. Results were analyzed using Xponent 3.1 software (Luminex) and graphed using Microsoft Excel to visualize changes in cytokine levels.
Immunohistochemical staining for immune cell localization
Paraffin-embedded tissue sections were deparaffinized and rehydrated using xylene, an ethanol gradient, and deionized water as per standard protocol. Antigen retrieval was performed using trypsin in a humidified chamber followed by steaming while treating tissue with target retrieval solution (Dako S1700) for 30 min. Following this incubation, the tissue sections were treated with hydrogen peroxide and then blocked with R.T.U. normal horse serum (Vector). Primary anti-CD14 antibody (Abcam) was applied at a 1:500 dilution followed by the secondary antibody (ImmPRESS Reagent Kit peroxidase, Vector MP-7401). After the incubation with the secondary antibody, visualization of the cells was performed using the DAB:Peroxidase Substrate Kit (Vector SK-4100). The tissue was then counterstained using hematoxylin (Vector H3401) and was processed through an alcohol gradient and xylene before application of a coverslip mounted using cytoseal XYL mounting media (Richard Allan Scientific 8312–4). Staining was performed by Paragon Bioservices. Levels of staining were assessed qualitatively in sections prepared from three mice at each time point.
Toxicity after a single N-9 exposure is localized to the cervix
Scoring system used for the assessment of cervicovaginal epithelial tissue damage subsequent to N-9 exposure
Description of epithelial damage
No epithelial disturbances or sloughing of epithelial cells
Light epithelial damage and disruption – localized loss of tissue integrity and epithelial sloughing over less than 5% of the epithelial surface, which is otherwise contiguous and intact
Moderate epithelial damage and disruption – Multiple areas of epithelial disturbance representing 5-25% of the total epithelial surface and small regions of sloughing that expose the basal cell layer
Severe epithelial damage and disruption – Sloughing over large sections of the epithelial surface (> 25%) that exposes the basal cell layer
In control animals, saline application caused no damage to the cervicovaginal epithelium. At 2 h post-exposure, the vaginal (Figure1B) and cervical (Figure1C) epithelia were unaffected by a single exposure to saline. Similarly, no damage to the vaginal (Figure1D) or cervical (Figure1E) epithelia was apparent after four daily exposures to saline. Similar results were obtained at days 2 and 3, and after post-exposure durations shorter (10 min) or longer (4 h and 8 h) than 2 h (data not shown). Saline controls were considered representative of healthy tissue, since mock-exposed tissues and saline-exposed tissues were indistinguishable (data not shown).
In sharp contrast, damage to the cervix was readily apparent by 10 min after a single application of N-9 (Figure2B), with swelling of cells in the columnar epithelium, sloughing of the superficial layers of the epithelium, and presumed apoptosis. Severe sloughing across most of the superficial epithelium (leaving the basal layer intact) was consistently observed in the cervix 2 h post-application (Figure2D). By 4 h post-exposure, there was scant superficial epithelium remaining with some foci showing complete epithelial denudation (Figure2F). At 8 h post-exposure, very little of the superficial columnar cell layer of the cervical epithelium remained, leaving large areas of the deeper basal cell layer almost completely exposed. The majority of the mucosa contained only one or two layers of basal cells with larger areas of complete epithelial denudation (Figure2H). By 24 h after N-9 application, however, the cervical epithelium more closely resembled saline-exposed tissue, suggesting a process of tissue repair during the preceding 16 hours (data not shown).
Cervical sensitivity to N-9 exposure decreases with increasing exposure number
Average damage scores for cervical epithelial tissues exposed to N-9
N-9 exposure duration
Exposure 1/Day 1
1.3 ± 0.3
3.0 ± 0.0
3.0 ± 0.0
3.0 ± 0.0
Exposure 4/Day 4
0.0 ± 0.0
1.0 ± 0.0
1.7 ± 0.3
0.7 ± 0.3
P value, Day 1 vs. Day 4
Pro-inflammatory cytokine release varies after multiple N-9 exposures
Cervicovaginal lavages were also collected during the multiple exposure experiments to assess the release of cytokines subsequent to single or multiple exposures to N-9. We hypothesized that comparisons of pro-inflammatory cytokines released on days 1 and 4 would reveal notable differences, given the considerable and significant histological differences between cervical tissues subjected to one or four daily exposures to N-9. Because previous in vitro, rabbit, and human studies identified IL-1β and IL-6 as significant predictors of cervicovaginal toxicity following single or multiple exposures to N-9[27, 28], the present studies were focused on these factors.
In contrast, IL-6 levels were consistent with the degree of cervical epithelial damage. On day 1 (Figure6C), IL-6 release was first detected at 2 h post-exposure and peaked at 4 h (~130 pg/ml) before returning to baseline levels. After four daily N-9 applications (Figure6D), IL-6 release was detected only at 2 h post-exposure at a considerably lower concentration (~50 pg/ml) relative to day 1. Both IL-6 release patterns paralleled the time course and severity of N-9-associated cervical epithelial damage. On day 1, the peak of IL-6 release corresponded with the severe damage to the cervical epithelia noted at 2–4 h post-exposure. On day 4, the comparatively lower level of IL-6 release was consistent with the reduced severity of epithelial damage and apparent tolerance to N-9 exposure, and coincided with the modest increase in epithelial damage observed at 4 h post-exposure.
CD14+ cell infiltration in the cervix increases following a single N-9 exposure but declines after repeated daily exposures
Previous studies of N-9 toxicity in the mouse revealed intense infiltration of CD45-positive immune cells and Ly6-positive neutrophils subsequent to a 2 h exposure to unformulated N-9[19, 25]. In preliminary experiments designed to expand these findings, mice were given a single application of unformulated 1% N-9 and sacrificed at 2, 4, or 24 h post-exposure. Cells isolated from excised cervicovaginal tissues before or after N-9 exposure were analyzed by flow cytometry to identify the following immune cell populations: CD4+/CD3+ T lymphocytes, CD8+/CD3+ T lymphocytes, Ly6G + neutrophils, and CD14+/CD11C- monocytes/macrophages. In addition to the abundance of infiltrating neutrophils following N-9 exposure, these experiments indicated a 50% increase in the number of CD14+/CD11c- cells at 2 h post-exposure (data not shown). In addition, monocyte/macrophage infiltration appeared to decrease by 4 h post-exposure and returned to control levels by 24 h post-exposure (data not shown).
Because peak cervical epithelial damage after four daily N-9 exposures was observed at 4 h post-exposure (Figure5 and Table2), similar analyses were performed on cervicovaginal tissues collected at 4 h post-exposure from mice after four daily N-9 applications. As was observed after a single N-9 exposure, few CD14+ cells were observed in the day 4 vaginal epithelium (Figure7E). In the cervical epithelium (Figure7F), CD14+ cells were present in greater numbers relative to cell numbers in the corresponding vaginal tissues. However, cell infiltration was clearly not as intense as was noted at 2 h on day 1. Furthermore, the intense cervical sub-surface staining seen on day 1 was not apparent on day 4; infiltrating CD14+ cells were only present deeper in the lamina propria. CD14+ cell staining in the cervix at 4 h and 24 h post-exposure was also reduced relative to levels noted in cervical tissues on day 1 (data not shown). These results again indicate a parallel between physical epithelial damage and CD14+ cell infiltration within the cervix; apparent tolerance to N-9 exposure was accompanied by considerably lower levels of monocyte/macrophage infiltration.
Early efforts to develop a safe and effective microbicide ended with the observation that N-9, which had been used safely as a spermicidal agent for over four decades, was not only clinically ineffective against HIV-1 transmission, but was also capable of significantly increasing the risk of HIV-1 acquisition after repeated use. These clinical trial results prompted a reassessment of mechanisms of N-9 toxicity and a general realization that a greater emphasis on pre-clinical microbicide safety was necessary.
One conclusion from post-failure analyses of N-9 microbicide development was that toxicity studies using the standard rabbit vaginal irritation (RVI) model provided an incomplete picture of the adverse effects of N-9 on the cervicovaginal epithelial tissues and the relevance of those effects to the risk of HIV-1 transmission. While the RVI model has provided important information regarding the safety of N-9 and other topical vaginal microbicides, there are limitations to the standard protocol. First, despite its demonstrated sensitivity to toxic topical agents, the RVI model does not assess product safety during the window of likely HIV-1 transmission. The standard RVI test protocol includes only one assessment of toxicity at 24 h after the final product application and does not provide for measures of toxicity at more acute post-exposure intervals, particularly the first hours after topical application when sexual intercourse and HIV-1 transmission are likely to occur. Our previous studies using the mouse model of cervicovaginal toxicity demonstrated that N-9- and C31G-mediated damage was greatest at 2 to 4 h post-exposure and was minimal or undetectable by 24 h post-application[19, 24, 25], presumably because epithelial repair mechanisms had restored the epithelium to its pre-exposure state. The standard RVI model would not reveal these important milestones in the time course of N-9 topical toxicity. Second, this model also differs from the human female reproductive tract (FRT) in that the rabbit FRT (i) does not undergo cyclic reproductive stages, (ii) is not colonized by lactobacillus (resulting in a lack of acidity within the vaginal tract), (iii) lacks the production of cervicovaginal mucus, and (iv) is characterized by a columnar epithelium in the upper vagina (cervicovagina) and a stratified squamous epithelium in the lower vagina (urovagina)[29–32].
We developed a Swiss Webster murine model to assess cervicovaginal tissue integrity and inflammation following exposure to candidate vaginal microbicides and to specifically address the need for an in vivo model system that can be used to provide pre-clinical results predictive of clinical trial outcomes. The Swiss Webster mouse is a readily accessible, outbred stock strain that has previously been used as a model for studies of various infectious cervicovaginal tract pathogens, including Chlamydia trachomatis, herpes simplex virus, and group B streptococci (GBS). These mice have also been used in various pre-clinical microbicide studies[33–37]. The Swiss Webster mouse model offers several distinct advantages over the RVI model and other approaches used for the evaluation of cervicovaginal toxicity and inflammation associated with exposure to topical microbicides. First, the Swiss Webster mouse is a relatively inexpensive animal model, permitting large, pre-clinical toxicity screens of candidate compounds under a variety of experimental conditions (including multiple exposure protocols) that can be used to evaluate cervicovaginal toxicity and inflammation at the cellular and tissue level prior to Phase I safety trials. Second, previously published observations from experiments involving this model[19, 25] have indicated close parallels to clinical findings, demonstrating the value of this model as a prescreening tool to prevent costly and time-consuming clinical trials on compounds with unacceptable safety profiles. Third, the mouse model, unlike the RVI model system, can be used to assess regional differences in cervicovaginal toxicity. This is an important feature of this animal model system, since topical toxicity can be tissue-specific, as we have demonstrated in past studies[19, 25, 38]. Consideration of regional differences in FRT toxicity may be relevant to understanding mechanisms of HIV-1 transmission, since non-human primate studies of SIV cervicovaginal infection suggest that HIV-1 transmission within the FRT may be regionally constrained[39, 40], perhaps by the nature of the epithelial barrier or by regional differences in the distribution of HIV-1-susceptible immune cell populations. The model, however, is not without its limitations: the lack of colonizing lactobacillus (addressed only in the non-human primate model); a higher cervicovaginal pH relative to the human FRT; and the use of Depo-Provera to pretreat the animals prior to experimentation.
The present studies, through the single N-9 exposure aspect of these experiments, have confirmed observations reported in previously published studies[19, 25]. First, the cervical epithelium is severely damaged by a single exposure to N-9, while the vaginal epithelium remains relatively intact. The damage to the cervical epithelium is characterized by breaks in the columnar tissue architecture and severe tissue sloughing. Second, N-9-associated cervical epithelial damage occurs relatively rapidly. After a single exposure to 1% N-9, the damage to the cervical epithelium was greatest at 2 to 4 h post-exposure. Third, physical damage can be accompanied by intense immune cell infiltration. Unlike the present studies, past experiments identified the infiltrating cells as positive for CD45, which is a pan-leukocyte cell surface marker. Finally, the damage caused by a single N-9 exposure is transient and resolved over a period of approximately 24 h post-exposure.
The single exposure results also suggest that tissue damage may not be strictly associated with the anatomy of the cervicovaginal tract. We consistently observed severe N-9-associated damage to the columnar epithelium of the cervix and minimal damage to the stratified squamous epithelium of the lower vagina. However, one of the vaginal sections (Figure3C, Day 2/Exposure 2, 2 h) shows intact stratified squamous epithelium adjacent to damaged columnar epithelium (roughly the lower half of the field), which is presumed to be part of the upper vaginal tract. Under Depo-Provera pre-treatment, the upper vaginal tract assumes a morphology typified by a single layer of columnar cells overlying 1–2 layers of basal cells. These observations indicate that epithelial damage subsequent to N-9 application is dependent on the architecture of the epithelial tissue rather than its anatomical location, and that a columnar epithelium, regardless of its location, is more susceptible to N-9 toxicity than a stratified squamous epithelium.
The present studies also provide new information regarding N-9 toxicity that is relevant to increases in HIV-1 transmission after repeated exposure to N-9. During repeated daily exposures to unformulated 1% N-9, the cervical epithelium appeared to become less sensitive to the degradative effects of N-9 application. By the fourth application, the damage caused by N-9 application was less and the peak damage was observed at 4 h post-exposure rather than at 2 h post-exposure as seen following the first application of N-9. This observation suggests the possibility that changes in the epithelial architecture after the initial exposure, insult, inflammation, and repair provide a protective mechanism against the effects of subsequent N-9 exposure.
This apparent tolerance to N-9 exposure after multiple applications may likely be related to changes in cervical tissue morphology observed during these studies. After multiple N-9 exposures, the tissue appeared to be metaplastic, forming multiple layers of stratified squamous epithelium instead of the usual single layer of columnar epithelium overlying one or two layers of basal epithelium. This effect has been observed subsequent to stress applied to tissue over time. The increased tolerance of this metaplastic tissue is consistent with the above conclusion that susceptibility to N-9-associated damage is dependent on tissue architecture rather than anatomical location, since the stratified cervical tissue observed in day 4 mice was more tolerant of N-9 exposure compared to the columnar cervical epithelial tissue found in day 1 mice. One focus of future studies will be to determine the amount of time required for repaired and tolerant tissues to return to their baseline structures and levels of susceptibility to damage.
The present studies also revealed new information about relationships between repeated N-9-associated damage and induced tissue inflammation. Following N-9 exposure, the release of the pro-inflammatory cytokines IL-1β and IL-6 was detected in vaginal lavages, reinforcing the roles for these cytokines as important mediators of the inflammatory response in the vaginal tract in response to microbicide application[27, 28]. However, only IL-6 release coincided with cervical epithelial damage (2–4 h post-exposure) after the initial N-9 application. In contrast, minimal amounts of IL-1β were detected on day 1. Conversely, IL-1β was released quickly (10 min post-exposure) and in relatively large amounts on day 4 relative to day 1. While IL-6 release was also detected on day 4, the magnitude of release was considerably less. In all cases, cytokine increases were transient and returned to control levels by 8 to 24 h post-exposure as tissue regeneration was in progress. Although the significance of these observations has not yet been determined, the pattern of cytokine release suggests an association with tissue regeneration following multiple N-9 exposures and the development of tolerance to N-9 application.
Subsequent to N-9 exposure, CD14+ monocytes/macrophages were also detected as part of the immune cell infiltrate. The intense, sub-surface presence of CD14+ immune cells after the first exposure to N-9 coincided with the cervical localization of epithelial damage, the peak severity of damage at 2 to 4 h post-exposure, and the detection of IL-6 in the vaginal lavage. The association between IL-6 release and the presence of CD14+ immune cells suggests that the source of the IL-6 may be the monocyte/macrophage population within the infiltrate[43, 44]. This hypothesis is also consistent with the concomitant decrease in CD14+ cells and reduction in released IL-6 at 8 and 24 h post-exposure, and with the association between the reduced levels of IL-6 and lower numbers of infiltrating CD14+ cells on day 4.
These studies provide new insights and raise new questions about cervicovaginal damage associated with multiple exposures to topical agents with epithelial toxicity. Future studies will need to explore several aspects of these results, including the underlying mechanisms of cervicovaginal epithelial regeneration and tolerance to toxic agents, and the involvement of the inflammatory response in the process of tissue recovery. Additional experiments will need to examine the effects of multiple exposures to toxic agents such as N-9 during a single day, since increases in the risk of HIV-1 acquisition were attributed to multiple uses of N-9 within a single 24 h period. Finally and most importantly, these studies suggest the need for multiple exposure protocols in future safety and efficacy assessments during the pre-clinical development of topical vaginal (and rectal) microbicides effective against HIV-1 transmission.
These studies were supported by a grant through the National Institute of Allergy and Infectious Diseases, National Institutes of Health (1 U19 AI076965). Dr. Krebs was also supported by faculty development funds provided by the Department of Microbiology and Immunology and the Institute for Molecular Medicine and Infectious Disease at the Drexel University College of Medicine.
- Global Report: UNAIDS report on the global AIDS epidemic 2010.http://www.unaids.org/globalreport/Global_report.htm,
- Ramjee G: Microbicide research: current and future directions. Curr Opin HIV AIDS. 2010, 5 (4): 316-321. 10.1097/COH.0b013e32833a9f66.View ArticlePubMedGoogle Scholar
- Nuttall J: Microbicides in the prevention of HIV infection: current status and future directions. Drugs. 2010, 70 (10): 1231-1243.PubMedGoogle Scholar
- Minces LR, McGowan I: Advances in the Development of Microbicides for the Prevention of HIV Infection. Curr Infect Dis Rep. 2010, 12 (1): 56-62. 10.1007/s11908-009-0076-5.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002, 360 (9338): 971-977. 10.1016/S0140-6736(02)11079-8.View ArticlePubMedGoogle Scholar
- Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, Rountree W, Troxler A, Dominik R, Roddy R: SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007, 2 (12): e1312-10.1371/journal.pone.0001312.View ArticlePubMedPubMed CentralGoogle Scholar
- Pirrone V, Wigdahl B, Krebs FC: The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011, 90 (3): 168-182. 10.1016/j.antiviral.2011.03.176.View ArticlePubMedGoogle Scholar
- Veazey RS: Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS. 2008, 3 (5): 567-573. 10.1097/COH.0b013e32830891bb.View ArticlePubMedPubMed CentralGoogle Scholar
- Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F: In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005, 39 (1): 1-8. 10.1097/01.qai.0000159671.25950.74.View ArticlePubMedGoogle Scholar
- Benes S, McCormack WM: Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother. 1985, 27 (5): 724-726. 10.1128/AAC.27.5.724.View ArticlePubMedPubMed CentralGoogle Scholar
- Kelly JP, Reynolds RB, Stagno S, Louv WC, Alexander WJ: In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother. 1985, 27 (5): 760-762. 10.1128/AAC.27.5.760.View ArticlePubMedPubMed CentralGoogle Scholar
- Asculai SS, Weis MT, Rancourt MW, Kupferberg AB: Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Agents Chemother. 1978, 13 (4): 686-690. 10.1128/AAC.13.4.686.View ArticlePubMedPubMed CentralGoogle Scholar
- Jennings R, Clegg A: The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. J Antimicrob Chemother. 1993, 32 (1): 71-82. 10.1093/jac/32.1.71.View ArticlePubMedGoogle Scholar
- Malkovsky M, Newell A, Dalgleish AG: Inactivation of HIV by nonoxynol-9. Lancet. 1988, 1 (8586): 645-View ArticlePubMedGoogle Scholar
- Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B: Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 1999, 43 (3): 157-173. 10.1016/S0166-3542(99)00044-3.View ArticlePubMedGoogle Scholar
- Polsky B, Baron PA, Gold JW, Smith JL, Jensen RH, Armstrong D: In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet. 1988, 1 (8600): 1456-View ArticlePubMedGoogle Scholar
- Singh B, Cutler JC, Utidjian HM: Studies on development of a vaginal preparation providing both prophylaxis against venereal disease, other genital infections and contraception. 3. In vitro effect of vaginal contraceptive and selected vaginal preparations of Candida albicans and Trichomonas vaginalis. Contraception. 1972, 5 (5): 401-411. 10.1016/0010-7824(72)90032-7.View ArticlePubMedGoogle Scholar
- Cook RL, Rosenberg MJ: Do spermicides containing nonoxynol-9 prevent sexually transmitted infections? A meta-analysis. Sex Transm Dis. 1998, 25 (3): 144-150. 10.1097/00007435-199803000-00007.View ArticlePubMedGoogle Scholar
- Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, Howett MK, Labib M, Rando R, Wigdahl B: Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother. 2004, 48 (5): 1837-1847. 10.1128/AAC.48.5.1837-1847.2004.View ArticlePubMedPubMed CentralGoogle Scholar
- Roddy RE, Cordero M, Cordero C, Fortney JA: A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993, 4 (3): 165-170.PubMedGoogle Scholar
- Chvapil M, Droegemueller W, Owen JA, Eskelson CD, Betts K: tudies of nonoxynol-9. I. The effect on the vaginas of rabbits and rats. Fertil Steril. 1980, 33 (4): 445-450.View ArticlePubMedGoogle Scholar
- Kaminsky M, Szivos MM, Brown KR, Willigan DA: Comparison of the sensitivity of the vaginal mucous membranes of the albino rabbit and laboratory rat to nonoxynol-9. Food Chem Toxicol. 1985, 23 (7): 705-708. 10.1016/0278-6915(85)90161-9.View ArticlePubMedGoogle Scholar
- Catalone BJ, Ferguson ML, Miller SR, Malamud D, Kish-Catalone T, Thakkar NJ, Krebs FC, Howett MK, Wigdahl B: Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure. Biomed Pharmacother. 2005, 59 (8): 460-468. 10.1016/j.biopha.2005.07.009.View ArticlePubMedGoogle Scholar
- Catalone BJ, Miller SR, Ferguson ML, Malamud D, Kish-Catalone T, Thakkar NJ, Krebs FC, Howett MK, Wigdahl B: Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. Biomed Pharmacother. 2005, 59 (8): 430-437. 10.1016/j.biopha.2005.07.008.View ArticlePubMedGoogle Scholar
- Catalone BJ, Kish-Catalone TM, Neely EB, Budgeon LR, Ferguson ML, Stiller C, Miller SR, Malamud D, Krebs FC, Howett MK: Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother. 2005, 49 (4): 1509-1520. 10.1128/AAC.49.4.1509-1520.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Roddy RE, Cordero M, Ryan KA, Figueroa J: A randomized controlled trial comparing nonoxynol-9 lubricated condoms with silicone lubricated condoms for prophylaxis. Sex Transm Infect. 1998, 74 (2): 116-119. 10.1136/sti.74.2.116.View ArticlePubMedPubMed CentralGoogle Scholar
- Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF: Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004, 71 (3): 761-769. 10.1095/biolreprod.104.029603.View ArticlePubMedGoogle Scholar
- Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001, 184 (4): 418-428. 10.1086/322047.View ArticlePubMedGoogle Scholar
- Noguchi K, Tsukumi K, Urano T: Qualitative and quantitative differences in normal vaginal flora of conventionally reared mice, rats, hamsters, rabbits, and dogs. Comparative medicine. 2003, 53 (4): 404-412.PubMedGoogle Scholar
- Costin GE, Raabe HA, Priston R, Evans E, Curren RD: Vaginal irritation models: the current status of available alternative and in vitro tests. Alternatives to laboratory animals: ATLA. 2011, 39 (4): 317-337.PubMedGoogle Scholar
- Eckstein P, Jackson MC, Millman N, Sobrero AJ: Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. Journal of reproduction and fertility. 1969, 20 (1): 85-93. 10.1530/jrf.0.0200085.View ArticlePubMedGoogle Scholar
- Castle PE, Hoen TE, Whaley KJ, Cone RA: Contraceptive testing of vaginal agents in rabbits. Contraception. 1998, 58 (1): 51-60. 10.1016/S0010-7824(98)00059-6.View ArticlePubMedGoogle Scholar
- Pal S, Fielder TJ, Peterson EM, de la Maza LM: Analysis of the immune response in mice following intrauterine infection with the Chlamydia trachomatis mouse pneumonitis biovar. Infect Immun. 1993, 61 (2): 772-776.PubMedPubMed CentralGoogle Scholar
- Cox F: Prevention of group B streptococcal colonization with topically applied lipoteichoic acid in a maternal-newborn mouse model. Pediatr Res. 1982, 16 (10): 816-819. 10.1203/00006450-198210000-00003.View ArticlePubMedGoogle Scholar
- Bourne N, Stegall R, Montano R, Meador M, Stanberry LR, Milligan GN: Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother. 2005, 49 (3): 1181-1183. 10.1128/AAC.49.3.1181-1183.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Milligan GN, Bernstein DI: Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology. 1997, 229 (1): 259-268. 10.1006/viro.1997.8441.View ArticlePubMedGoogle Scholar
- Milligan GN, Chu CF, Young CG, Stanberry LR: Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. Biol Reprod. 2004, 71 (5): 1638-1645. 10.1095/biolreprod.104.029215.View ArticlePubMedGoogle Scholar
- Lozenski K, Kish-Catalone T, Pirrone V, Rando RF, Labib M, Wigdahl B, Krebs FC: Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. Journal of biomedicine & biotechnology. 2011, 2011: 941061-View ArticleGoogle Scholar
- Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010, 464 (7286): 217-223. 10.1038/nature08757.View ArticlePubMedGoogle Scholar
- Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG: Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009, 458 (7241): 1034-1038. 10.1038/nature07831.View ArticlePubMedPubMed CentralGoogle Scholar
- Pudney J, Quayle AJ, Anderson DJ: Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005, 73 (6): 1253-1263. 10.1095/biolreprod.105.043133.View ArticlePubMedGoogle Scholar
- Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006, 6: 90-10.1186/1471-2334-6-90.View ArticlePubMedPubMed CentralGoogle Scholar
- Grimm MC, Pavli P, Van de Pol E, Doe WF: Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa–implications for pathogenesis. Clin Exp Immunol. 1995, 100 (2): 291-297.View ArticlePubMedPubMed CentralGoogle Scholar
- Clahsen T, Schaper F: Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration. J Leukoc Biol. 2008, 84 (6): 1521-1529. 10.1189/jlb.0308178.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/2050-6511/13/9/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.